<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To examine the effects of intraventricular pre-treatment with a combination of recombinant adeno-associated virus vectors encoding VEGF (rAAV-VEGF) and Ang1 (rAAV-Ang1) on early <z:hpo ids='HP_0001297'>stroke</z:hpo> in a rat model of transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (tMCAO) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: rAAV-VEGF/rAAV-Ang1 or rAAV-VEGF/rAAV-null vector was delivered into the lateral ventricles of 48 rats </plain></SENT>
<SENT sid="2" pm="."><plain>Eight weeks later, the rats were subjected to tMCAO for 2 hours </plain></SENT>
<SENT sid="3" pm="."><plain>During the early stages of ischemic reperfusion, VEGF and Ang1 expression levels, blood-brain barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>) permeability and cerebral microvessel density were determined and compared statistically between groups </plain></SENT>
<SENT sid="4" pm="."><plain>Cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and modified neurological severity scores (NSS) were also determined to evaluate the therapeutic efficacy of rAAV-VEGF/rAAV-Ang1 </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Intraventricular application of rAAV-VEGF/rAAV-Ang1, 8 weeks before tMCAO, resulted in VEGF and Ang1 overexpression, and significantly decreased Evans blue permeability following <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> (p&lt;0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>The microvessel density in the peri-<z:mpath ids='MPATH_124'>infarct</z:mpath> zone was significantly increased in the rAAV-VEGF/rAAV-Ang1 group compared with the rAAV-VEGF/rAAV-null group (p&lt;0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>Cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and NSS in the rAAV-VEGF/rAAV-Ang1 group were significantly decreased compared with the rAAV-VEGF/rAAV-null group (p&lt;0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: In <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, the combination of Ang1 and VEGF could be used early to promote the formation of mature neovessels and protect the injured cells, without inducing the side effects on <z:chebi fb="2" ids="33602">BBB</z:chebi> permeability </plain></SENT>
<SENT sid="9" pm="."><plain>Early intraventricular injection of mixed rAAV-VEGF and rAAV-Ang1 may be a favorable therapeutic strategy in gene therapy for experimental <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>